Home » Neogenix Receives Orphan Drug Status for Pancreatic Cancer Treatment
Neogenix Receives Orphan Drug Status for Pancreatic Cancer Treatment
Neogenix announced Monday that the U.S. Food and Drug Administration has granted orphan drug designation to the company’s product candidate ensituximab (monoclonal antibody NPC-1C) for the treatment of pancreatic cancer.
ADVFN
ADVFN
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May